Clinical Trials on Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma

Total 6984 results

Pierian Biosciences

Terminated

Validation of the MiCK Assay (MiCK Assay)

Mesothelioma, Small Cell Lung Cancer, NSCLC

United States
ArriVent BioPharma, Inc.

Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768I

United States, Australia, Spain, United Kingdom, France, Italy, China, Korea, Republic of, Canada, Japan, Netherlands
Amgen

Not yet recruiting

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) (Eucalyptus)

Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
AbbVie

Active, not recruiting

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

Advanced Solid Tumors Cancer | Non Small Cell Lung Cancer (NSCLC)

United States, Australia, France, Israel, Japan, Korea, Republic of, Spain, Taiwan
Eckhard Podack

Withdrawn

Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | NSCLC | Lung Cancer | Non-small-cell Lung Carcinoma
Genzyme, a Sanofi Company

Completed

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.

Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line

United States, Czech Republic, Hungary
Radboud University Medical Center

Completed

Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy

NSCLC | Locally Advanced Non-Small Cell Lung Cancer

Netherlands
Julia K. Rotow, MD
Inivata

Active, not recruiting

Plasma-Adapted First-Line Pembro In NSCLC

Metastatic Non-Small Cell Lung Cancer | NSCLC Stage IV

United States
Chao Huang
University of Kansas Medical Center

Active, not recruiting

Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy

Advanced Solid Tumor | Non-small Cell Lung Cancer (NSCLC)

United States
Yantai LNC Biotechnology Singapore PTE. LTD.

Not yet recruiting

Clinical Study of 18F-Alfatide Injection PET/CT

Non-Small Cell Lung Cancer NSCLC

China
AstraZeneca

Active, not recruiting

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON)

Non Small Cell Lung Cancer NSCLC

Poland, United States, Taiwan, Thailand, Vietnam, Korea, Republic of, United Kingdom, Brazil, Hungary, Japan, Mexico, Peru, Russian Federation, China, Germany, South Africa, Ukraine, Bulgaria, Hong Kong
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

NSCLC (Non-small-cell Lung Cancer)

China
Palobiofarma SL
Novartis; H. Lee Moffitt Cancer Center and Research Institute

Completed

Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO)

Non-small Cell Lung Cancer (NSCLC)

United States
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Non-Small-Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor Mutations

United States
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Non-small Cell Lung Cancer (NSCLC)

China, Australia, United States, Turkey, Chile, Taiwan, Denmark, France, Spain, Argentina, Italy, Netherlands, Thailand, Korea, Republic of
Academic Thoracic Oncology Medical Investigators...
AstraZeneca

Completed

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Non-Small Cell Lung Cancer NSCLC

United States
Samsung Medical Center
AstraZeneca

Completed

Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC) (BLOSSOM)

Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of
University Health Network, Toronto

Completed

Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT (SBRT FLT-PET)

Non Small Cell Lung Cancer (NSCLC)

Canada
Merck Sharp & Dohme LLC

Completed

Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)

Non Small Cell Lung Cancer (NSCLC)
Maastricht Radiation Oncology
Anticancer Fund, Belgium; Reliable Cancer Therapies

Terminated

Nitroglycerin in Non-small Cell Lung Cancer (Nitroglycerin)

Non Small Cell Lung Cancer (NSCLC)

Netherlands
Tasly Pharmaceuticals, Inc.

Unknown

A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)

China
Tongji University

Recruiting

A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations

NSCLC, Stage IIIA | EGF-R Negative Non-Small Cell Lung Cancer | ALK Negative NSCLC

China
Massachusetts General Hospital

Active, not recruiting

The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance

Non Small Cell Lung Cancer | Mesothelioma | Small-cell Lung Cancer | Cognitive Behavioral Therapy

United States
Joseph J. Cullen, MD, FACS
National Cancer Institute (NCI); National Institutes of Health (NIH); Holden...

Recruiting

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (XACT-LUNG)

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | NSCLC | Nonsmall Cell Lung Cancer | Non-Small-Cell Lung Carcinoma

United States
University College, London
Cancer Research UK

Recruiting

TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO

Small Cell Lung Cancer | Lung Cancer, Non-small Cell | Pleural Mesothelioma

United Kingdom
Vestre Viken Hospital Trust
Oslo University Hospital; University Hospital of North Norway; Helse Stavanger... and other collaborators

Recruiting

Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer (LUNGVAC)

Oncology | NSCLC Stage IV | NSCLC, Stage III

Norway
iTeos Belgium SA

Recruiting

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Metastatic NSCLC | Stage III NSCLC

United States, Belgium, Spain, Switzerland, Italy, France, Canada, Poland, Czechia
SystImmune Inc.

Recruiting

Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Breast Cancer | Small Cell Lung Cancer | Nasopharyngeal Cancer | Esophageal Cancer | NSCLC | Lung Cancer | Non Small Cell Lung Cancer | SCLC | NPC

United States
Ohio State University Comprehensive Cancer Center

Withdrawn

Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy

Stage IIIB Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Stage III Malignant Mesothelioma | Stage IV Malignant Mesothelioma
Augusta University

Terminated

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Non Small Cell Lung Cancer | Malignant Mesothelioma | Urothelial Carcinoma | Non-squamous Non-small-cell Lung Cancer

United States
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Non-small Cell Lung Cancer (NSCLC)

China, Taiwan, United States, Australia, Israel, Hong Kong, Chile, Korea, Republic of, Canada, Malaysia, Thailand
Kai-Uwe Schmitt, PhD, MEng, ICID

Recruiting

Digital Lifestyle Intervention for Lung Cancer Survivors After Inpatient Rehabilitation (QUALUCA)

Non-Small Cell Lung Cancer (NSCLC)

Switzerland
Pfizer

Completed

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

NSCLC (Non-small Cell Lung Cancer)

Hong Kong, China, Taiwan, Malaysia, Thailand
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Non-small Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor (EGFR) Mutations

United States
Memorial Sloan Kettering Cancer Center

Completed

Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer

Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC)

United States
Washington University School of Medicine
Boston Scientific Corporation

Completed

EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung Cancer

NSCLC | Non Small Cell Lung Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

Recurrent Non-Small Cell Lung Carcinoma | Recurrent Pleural Malignant Mesothelioma | Stage III Pleural Malignant Mesothelioma AJCC v7 | Stage IV Pleural Malignant Mesothelioma AJCC v7 | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | HLA-A*0201 Positive... and other conditions

United States
Novartis Pharmaceuticals

Terminated

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Advanced Non Small Cell Lung Cancer (NSCLC)

France, Italy, Taiwan, Spain, Netherlands, Japan, Hong Kong, Korea, Republic of, Norway, United States, United Kingdom, Poland
Icahn School of Medicine at Mount Sinai

Recruiting

Pembrolizumab for Advanced NSCLC and PS 2-3

Non-Small Cell Lung Cancer (NSCLC)

United States
AstraZeneca

Completed

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC)

Non - Small Cell Lung Cancer NSCLC

United States, France, Germany, Italy, United Kingdom, Belgium, Poland, Romania, Taiwan, Thailand, Canada, Korea, Republic of, Czechia, Hungary, Japan, Russian Federation, Hong Kong, Spain, Netherlands, Greece, Australia, Serbia, Bu... and more
University of Miami

Terminated

Safety of LEAD Radiotherapy Plus Chemoradiation in Patients With Bulky Stage III Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | NSCLC

United States
University of Wisconsin, Madison
National Cancer Institute (NCI)

Completed

Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditions

United States
Jiangsu Healthy Life Innovation Medical Technology...

Not yet recruiting

Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment

Non-small Cell Lung Cancer (NSCLC)

China
Massachusetts General Hospital

Recruiting

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

Non-Small Cell Lung Cancer (NSCLC)

United States
Massachusetts General Hospital
Genentech, Inc.

Unknown

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States
National Taiwan University Hospital

Unknown

Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation

Non-small Cell Lung Cancer(NSCLC)

Taiwan
Hoffmann-La Roche

Active, not recruiting

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

Metastatic Melanoma | Non-small Cell Lung Cancer (NSCLC) | Solid Tumors | Esophageal Squamous Cell Carcinoma (ESCC) | Small Cell Lung Cancer (SCLC)

United States, Korea, Republic of, Denmark, France, Spain, New Zealand
Takeda

Recruiting

A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC) (Brilliant)

Non-small Cell Lung Cancer (NSCLC)

China
Pfizer

Recruiting

Lorlatinib Continuation Study

NSCLC | Non-Small-Cell Lung Cancer

Spain, China, Taiwan, France, Singapore, Japan, United States
First People's Hospital of Hangzhou
Hangzhou Cancer Hospital

Recruiting

A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

Non Small Cell Lung Cancer | EGFR Activating Mutation | Stage III NSCLC

China

Clinical Trials on Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations